Latest News
Tegoprazan NDA Seeks FDA Approval for 3 GERD Indications
12 minutes ago
The NDA is supported by data from the phase 3 TRIUMpH clinical program and seeks approval for heartburn in NERD, healing of erosive esophagitis, and maintenance of healing.
Predictors Identified for Super-Responder Status to Dupilumab in Atopic Dermatitis
22 minutes ago
In this retrospective single-center analysis, adult patients with moderate-to-severe atopic dermatitis treated with dupilumab were evaluated for super responder status.
Quality of Life and GI Tolerability in ATTR-CM Management
1 hour ago
The panel focuses on how quality of life considerations shape ATTR-CM management. Beyond survival and hospitalization outcomes, many patients most value being able to remain mobile and independent—continuing activities such as walking, gardening, or caring for grandchildren. Even subjective concerns like weight loss or appearing “frail” can meaningfully affect how patients feel about their health. Managing symptoms of congestion and reducing the need for frequent diuretic adjustments also plays an important role in daily well-being. The discussion then highlights recent data from HFSA showing that vutrisiran was associated with fewer gastrointestinal symptoms, such as diarrhea and constipation. The panel found this particularly interesting in wild-type ATTR-CM, where GI involvement is not always recognized. Improvements in GI comfort can support better nutrition, energy, and overall day-to-day function. Across the conversation, the experts emphasize that maintaining function and stability over time is often the clinical outcome patients value most.
Evaluating Long-Term Remission and Disease Control with Bimekizumab in Psoriasis
1 hour ago
In this episode, the panelists review long-term efficacy data for bimekizumab presented at EADV 2025, focusing on sustained remission and disease control in psoriasis. The experts highlight that approximately 49% of patients maintained complete skin clearance (PASI 100) from month 4 through year 4, with about 72% sustaining complete or near-complete clearance over the same period. They interpret these findings as strong evidence of durability and depth of response, underscoring bimekizumab’s ability to maintain remission over years rather than months. The discussion also includes nail outcomes, with nearly 80% of patients maintaining NAPSI 0, indicating resolution of nail involvement—an important factor given its association with psoriatic arthritis risk. The panelists emphasize that by achieving and maintaining high levels of clearance in both skin and nails, bimekizumab may help interrupt the inflammatory progression that leads to PsA, reinforcing its role in comprehensive disease control.
Severe Pediatric Dermatoses: Diagnostic Pitfalls and Early Systemic Therapy
1 hour ago
Explore diagnostic challenges in severe pediatric skin disease, common management pitfalls, and when to escalate to systemic or biologic therapy.